Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Alkermes plc

Biopharma SG&A Strategies: Alkermes vs. Corcept

__timestampAlkermes plcCorcept Therapeutics Incorporated
Wednesday, January 1, 201419990500034916000
Thursday, January 1, 201531155800036949000
Friday, January 1, 201637413000045240000
Sunday, January 1, 201742157800062416000
Monday, January 1, 201852640800081289000
Tuesday, January 1, 2019599449000100359000
Wednesday, January 1, 2020538827000105326000
Friday, January 1, 2021560977000122356000
Saturday, January 1, 2022605747000152848000
Sunday, January 1, 2023689751000184259000
Monday, January 1, 2024645238000
Loading chart...

In pursuit of knowledge

Navigating SG&A Expenses: A Tale of Two Biopharma Companies

In the competitive landscape of biopharmaceuticals, effective cost management is crucial. Over the past decade, Alkermes plc and Corcept Therapeutics Incorporated have demonstrated contrasting strategies in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc's SG&A expenses surged by approximately 245%, reflecting a strategic investment in growth and expansion. In contrast, Corcept Therapeutics Incorporated exhibited a more conservative increase of around 428%, indicating a focus on streamlined operations and efficiency. This divergence highlights the varied approaches companies take in balancing operational costs with strategic objectives. As the industry evolves, understanding these financial dynamics offers valuable insights into corporate strategy and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025